AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Study acronym: AMAZE 1
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 7 of 24 entries
    • Site details revised at 12 of 72 sites
  2. Study sites revised (72)v6
  3. Site details revised at 9 of 72 sitesv5
  4. Study sites revised (72)v4
  5. Study sites revised (72)v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites revised (72)
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
269 trials monitored
See 14 trials at risk
Obesity
3,903 trials monitored
See 160 trials at risk
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Trial Details
NCT Number NCT07339423
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 1,150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov